Andelyn Biosciences, a cell and gene therapy CDMO, unveiled a new manufacturing headquarters in Ohio, more than tripling its production footprint.
The Andelyn Corporate Center in Columbus, Ohio, adds 180,000 square feet of office, lab and manufacturing space to the company’s existing footprint, it said in a June 22 press release.
The company also operates the Andelyn Development Center for preclinical non-cGMP activities plus the Andelyn Plasmid Center for research and cGMP plasmid production, both in Columbus.
Andelyn's new plant features 16 cGMP modular manufacturing suites with upstream, downstream, solution prep and filling capabilities, plus control labs and warehouse and office space. This facility supports Andelyn’s "concept-to-commercialization" range of services.
The cost of the project wasn’t disclosed.
The company was formed in 2020 by the Nationwide Children’s Hospital’s Abigail Wexner Research Institute (AWRI) as a for-profit enterprise, with revenues going toward supporting nonprofit research at AWRI.
At the time of Andelyn’s founding, AWRI was operating a 9,000-square-foot clinical supply facility for gene therapies.